Home > Formulary : Adult > Recent Decisions > 2025 >
Decisions 28th January 2025
The following decisions were made at the Joint Formulary Group meeting held on Tuesday 28th January:
New Drug Requests
Indocyanine Green Dye (TLS Red)
-
Approved as a diagnostic tool for imaging in surgery as per trust protocols
Shared Care Protocols
-
Dopamine agonists (Cabergoline, Bromocriptine and Quinagolide) shared care protocol updated.
-
Note: the updated SCP includes the addition of Quinagolide, therefore the traffic light status of Quinagolide now changed from TLS Red to Amber 3 months with the shared care protocol as agreed at a previous JFG meeting.
-
Adult ADHD medications (Methylphenidate, Atomoxetine, Dexamfetamine and Lisdexamfetamine) shared care protocols updated.
-
Note: the updated adult ADHD SCPs are on new national SCP templates. Monitoring is in line with BNSSG specialist ADHD medicines monitoring LES.
Other discussions/decisions
-
"Mesalazine Prescribing Guidance" approved
-
Cyanocobalamin injection has been discontinued. Formulary listing for cyanocobalamin amended to reflect oral tablets are the only formulation currently available.
-
Potassium Chloride oral solution remains on the Adults formulary as TLS Blue following the discontinuation of Kay-Cee-L syrup noting this is unlicensed. Sando K effervescent tablets remain first line, however note that for patients requiring doses of less than 12mmol of potassium, part dosing of Sando-K effervescent tablets is not routinely recommended, but can be done if unlicensed specials are not available. For further information see the NPSA Alert here.
-
Discussion on testosterone gel/menopause specialist reopened to address primary care monitoring and funding. Further work to continue outside the Joint Formulary Group.
- Sumatriptan for cluster headaches - clarification on TLS of the available formulations. Sumatriptan (subcutaneous) is TLS green and Sumatriptan (intranasal) (off-label) is TLS blue.